Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe
B. Karo (Berlin, Germany), A. Kohlenberg (Stockholm, Sweden), V. Hollo (Stockholm, Sweden), R. Duarte (Porto, Portugal), L. Fiebig (Morogoro, Tanzania), S. Jackson (Dublin, Ireland), C. Kearns (Belfast, United Kingdom), C. KöDmöN (Stockholm, Sweden), M. Korzeniewska-Kosela (Warsaw, Poland), D. Papaventsis (Athens, Greece), I. Solovic (Vysne Hagy, Slovakia), D. Van Soolingen (Bilthoven, Netherlands), M. van der Werf (Stockholm, Sweden)
Source: International Congress 2018 – New developments in tuberculosis
Session: New developments in tuberculosis
Session type: Oral Presentation
Number: 1956
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Karo (Berlin, Germany), A. Kohlenberg (Stockholm, Sweden), V. Hollo (Stockholm, Sweden), R. Duarte (Porto, Portugal), L. Fiebig (Morogoro, Tanzania), S. Jackson (Dublin, Ireland), C. Kearns (Belfast, United Kingdom), C. KöDmöN (Stockholm, Sweden), M. Korzeniewska-Kosela (Warsaw, Poland), D. Papaventsis (Athens, Greece), I. Solovic (Vysne Hagy, Slovakia), D. Van Soolingen (Bilthoven, Netherlands), M. van der Werf (Stockholm, Sweden). Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe. 1956
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Mutation analysis and treatment outcomes of Isoniazid monoresistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009
Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region> Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013